CO2021014835A2 - Ácidos grasos poliinsaturados de cadena muy larga, derivados hidroxilados elovanoides y métodos de uso - Google Patents

Ácidos grasos poliinsaturados de cadena muy larga, derivados hidroxilados elovanoides y métodos de uso

Info

Publication number
CO2021014835A2
CO2021014835A2 CONC2021/0014835A CO2021014835A CO2021014835A2 CO 2021014835 A2 CO2021014835 A2 CO 2021014835A2 CO 2021014835 A CO2021014835 A CO 2021014835A CO 2021014835 A2 CO2021014835 A2 CO 2021014835A2
Authority
CO
Colombia
Prior art keywords
methods
fatty acids
long chain
polyunsaturated fatty
hydroxylated
Prior art date
Application number
CONC2021/0014835A
Other languages
English (en)
Inventor
Nicolas Bazan
Haydee E P Bazan
Nicos A Petasis
Original Assignee
Univ Louisiana State
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State, Univ Southern California filed Critical Univ Louisiana State
Publication of CO2021014835A2 publication Critical patent/CO2021014835A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan métodos para usar compuestos, composiciones farmacéuticas, composiciones cosméticas y dermatológicas o composiciones de suplementos nutricionales, que comprenden ácidos grasos poliinsaturados de cadena muy larga omega-3 (VLC-PUFA n-3) y/o sus derivados hidroxilados endógenos, conocidos como elovanoides para favorecer la protección, prevención y el tratamiento de alteraciones de la superficie ocular, como queratoconjuntivitis seca y afecciones inflamatorias de la superficie ocular.
CONC2021/0014835A 2019-04-04 2021-11-03 Ácidos grasos poliinsaturados de cadena muy larga, derivados hidroxilados elovanoides y métodos de uso CO2021014835A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962829322P 2019-04-04 2019-04-04
PCT/US2020/026919 WO2020206448A1 (en) 2019-04-04 2020-04-06 Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Publications (1)

Publication Number Publication Date
CO2021014835A2 true CO2021014835A2 (es) 2022-04-08

Family

ID=72667028

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0014835A CO2021014835A2 (es) 2019-04-04 2021-11-03 Ácidos grasos poliinsaturados de cadena muy larga, derivados hidroxilados elovanoides y métodos de uso

Country Status (7)

Country Link
US (1) US20220226270A1 (es)
EP (1) EP3946308A4 (es)
AU (1) AU2020253578A1 (es)
CA (1) CA3136137A1 (es)
CL (1) CL2021002597A1 (es)
CO (1) CO2021014835A2 (es)
WO (1) WO2020206448A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547080A (ja) * 2019-09-04 2022-11-10 ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ 超長鎖多価不飽和脂肪酸であるエロバノイドヒドロキシル化誘導体、および使用方法
AU2020402031A1 (en) * 2019-12-09 2022-06-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Biomolecule for treatment of corneal pathologies
DE102020007494A1 (de) 2020-12-08 2022-06-09 Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts Antientzündliche Oxylipine
WO2022140418A1 (en) * 2020-12-21 2022-06-30 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE504557T1 (de) * 2000-02-16 2011-04-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
CN103191129A (zh) * 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
US20120071558A1 (en) * 2008-01-28 2012-03-22 Anderson Robert E Compositions of very long chain polyunsaturated fatty acids and methods of use
US20130190399A1 (en) * 2009-10-31 2013-07-25 Martek Biosciences Corporation Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA)
US8865685B2 (en) * 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
EP2664330A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Zusammensetzung und Arzneimittel enthaltend Omega-3-Fettsäuren sowie einen Glucosaminoglucan
US9770426B2 (en) * 2013-01-11 2017-09-26 Massachusetts Eye And Ear Infirmary CYP450 lipid metabolites reduce inflammation and angiogenesis
CA3014033C (en) * 2015-02-09 2024-02-27 University Of Southern California Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases
CA3019028A1 (en) * 2016-04-01 2017-10-05 Omeicos Therapeutics Gmbh Analogs of cyp-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation
EP3601207A4 (en) * 2017-03-20 2020-11-25 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College VERY LONG CHAIN MULTIPLE UNSATURATED FATTY ACIDS, ELOVANOIDHYDROXYLATED DERIVATIVES AND METHOD OF USES
NO345574B1 (en) * 2018-06-19 2021-04-26 Epax Norway As Composition for treatment of dry eye disease and meibomianitis

Also Published As

Publication number Publication date
EP3946308A1 (en) 2022-02-09
AU2020253578A1 (en) 2021-11-04
US20220226270A1 (en) 2022-07-21
CL2021002597A1 (es) 2022-07-29
WO2020206448A1 (en) 2020-10-08
CA3136137A1 (en) 2020-10-08
EP3946308A4 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
CO2021014835A2 (es) Ácidos grasos poliinsaturados de cadena muy larga, derivados hidroxilados elovanoides y métodos de uso
ECSP11010746A (es) Salicilatos acetilados con ácidos grasos y sus usos
EA201790027A1 (ru) Твердая пероральная лекарственная форма липофильных соединений
GT200600463A (es) Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas
AR048613A1 (es) Expresion de las desaturasas de acidos grasos en maiz
MX2021004999A (es) Administracion de butirato, beta-hidroxibutirato, cannabidiol y compuestos relacionaods en seres humanos.
BR112019024623A2 (pt) Uso de uma esterase para aumentar teor de éster de etila em meios de fermentação
CO2021011652A2 (es) Ésteres de ácido graso como agentes anti-malassezia
AR105190A1 (es) Composiciones nutricionales y métodos para promover el desarrollo cognitivo
CL2019003072A1 (es) Composiciones nutricionales y farmacéuticas encapsuladas.
CY1122591T1 (el) Νεα cυρ-εικοσανοειδη παραγωγα
BR112016026660A2 (pt) ?produto extemporâneo para cuidados cosméticos e/ou dermatológicos, e, kit de preparação extemporânea de uma composição cosmética e/ou dermatológica?
MX2021009825A (es) Suplemento alimenticio.
MX2018000847A (es) Analogos metabolicamente robustos de cyp-eicosanoides para el tratamiento de enfermedades cardiacas.
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
CO2021000418A2 (es) Composiciones de ácidos grasos poliinsaturados enriquecidos con ala
WO2012075093A3 (en) Topical formulations for administration of omega-3 fatty acids
CL2020002644A1 (es) Composición para modular genes responsables de las funciones generales de la piel, que comprende la combinación de un extracto de hymenaea courbaril y una mezcla de cocoilaminoácidos de sodio y sarcosina y aspartato de potasio y aspartato de magnesio (divisional de la solicitud 03354-2018)
BR112018070194A2 (pt) composto e composição para uso
CL2021002080A1 (es) Composición para su uso en el tratamiento de la piscirickettsiosis.
PE20170250A1 (es) Composiciones estructuradas de grasa vegetal, proceso para obtener dicha composicion estructurada de grasas, uso de la composicion estructurada de grasas en la preparacion de una composicion cosmetica, composicion cosmetica y producto que comprende dicha composicion estructurada de grasas
CL2017002828A1 (es) Composición para tratamiento de estrés oxidativo y enfermedad cardiovascular
AR044623A1 (es) Grasa vegetal modificada
EA201792685A1 (ru) Фармацевтическая композиция для лечения воспалительных изменений прямой кишки
PE20230178A1 (es) Composiciones enriquecidas de acidos grasos poliinsaturados